NASDAQ:BNTC Benitec Biopharma (BNTC) Stock Price, News & Analysis → Warning: this could blow your mind (From DTI) (Ad) Free BNTC Stock Alerts $5.25 +0.12 (+2.34%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$5.05▼$5.2750-Day Range$2.80▼$5.6252-Week Range$1.86▼$9.01Volume20,970 shsAverage Volume15,254 shsMarket Capitalization$13.60 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Benitec Biopharma alerts: Email Address Benitec Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside90.5% Upside$10.00 Price TargetShort InterestHealthy0.22% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.39Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.72 out of 5 starsMedical Sector451st out of 938 stocksPharmaceutical Preparations Industry211th out of 425 stocks 3.5 Analyst's Opinion Consensus RatingBenitec Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, Benitec Biopharma has a forecasted upside of 90.5% from its current price of $5.25.Amount of Analyst CoverageBenitec Biopharma has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.22% of the float of Benitec Biopharma has been sold short.Short Interest Ratio / Days to CoverBenitec Biopharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Benitec Biopharma has recently decreased by 68.32%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBenitec Biopharma does not currently pay a dividend.Dividend GrowthBenitec Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BNTC. Previous Next 3.5 News and Social Media Coverage News SentimentBenitec Biopharma has a news sentiment score of 1.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Benitec Biopharma this week, compared to 0 articles on an average week.Search Interest3 people have searched for BNTC on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Benitec Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.30% of the stock of Benitec Biopharma is held by insiders.Percentage Held by Institutions52.19% of the stock of Benitec Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioBenitec Biopharma has a P/B Ratio of 43.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressA lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. Click here to jump in on the next one About Benitec Biopharma Stock (NASDAQ:BNTC)Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.Read More BNTC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BNTC Stock News HeadlinesMarch 24, 2024 | insidermonkey.com11 Best ASX Stocks To Buy NowFebruary 25, 2024 | msn.comBenitec Biopharma (BNTC) Price Target Increased by 66.67% to 10.20March 28, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.February 13, 2024 | finance.yahoo.comBenitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational UpdateNovember 30, 2023 | finance.yahoo.comHere's Why Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Compensation Is The Least Of Shareholders ConcernsNovember 30, 2023 | finance.yahoo.comBenitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular DystrophyNovember 19, 2023 | morningstar.comBenitec Biopharma Inc BNTCNovember 17, 2023 | finance.yahoo.comBenitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare ConferenceMarch 28, 2024 | WealthPress (Ad)A lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. November 15, 2023 | finanznachrichten.deBenitec Biopharma Inc.: Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational UpdateNovember 14, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Benitec Biopharma (BNTC), Rezolute (RZLT)November 13, 2023 | finance.yahoo.comBenitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational UpdateSeptember 27, 2023 | msn.comJMP Securities Maintains Benitec Biopharma (BNTC) Market Outperform RecommendationSeptember 26, 2023 | markets.businessinsider.comJMP Securities Sticks to Its Buy Rating for Benitec Biopharma (BNTC)September 21, 2023 | finance.yahoo.comBenitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational UpdateAugust 21, 2023 | finance.yahoo.comCitadel Advisors LLC Acquires New Stake in Benitec Biopharma IncAugust 11, 2023 | finance.yahoo.comBenitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public OfferingAugust 9, 2023 | msn.comBenitec Biopharma prices $30M equity offeringAugust 9, 2023 | finance.yahoo.comBenitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public OfferingAugust 2, 2023 | msn.comBenitec Biopharma (BNTC) Price Target Increased by 1600.00% to 69.36July 28, 2023 | barrons.comBenitec Biopharma Inc.July 27, 2023 | finance.yahoo.comBenitec Biopharma Announces 1-for-17 Reverse Stock Split Effective July 26, 2023June 26, 2023 | marketwatch.comBenitec Biopharma Receives FDA Clearance of IND for BB-301June 26, 2023 | marketwatch.comBenitec Biopharma Shares Double on FDA ClearanceJune 26, 2023 | msn.comWhat In The World Is Going On With Benetic Biopharma (BNTC) StockJune 26, 2023 | finance.yahoo.comBenitec Biopharma Receives FDA Clearance of the IND for BB-301 for the Treatment of Oculopharyngeal Muscular DystrophyMay 18, 2023 | msn.comJMP Securities Reiterates Benitec Biopharma (BNTC) Market Outperform RecommendationSee More Headlines Receive BNTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Benitec Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/13/2024Today3/28/2024Next Earnings (Estimated)5/20/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BNTC CUSIPN/A CIK1808898 Webwww.benitec.com Phone510-780-0819Fax61 (0)3 9966-9923Employees18Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+94.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,560,000.00 Net MarginsN/A Pretax Margin-35,754.10% Return on Equity-204.34% Return on Assets-142.81% Debt Debt-to-Equity Ratio0.01 Current Ratio3.62 Quick Ratio3.62 Sales & Book Value Annual Sales$80,000.00 Price / Sales166.08 Cash FlowN/A Price / Cash FlowN/A Book Value$0.12 per share Price / Book42.75Miscellaneous Outstanding Shares2,590,000Free Float2,481,000Market Cap$13.29 million OptionableNo Data Beta1.02 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Jerel A. Banks M.D. (Age 49)Ph.D., Executive Chairman & CEO Comp: $848.07kMs. Megan Joan Boston BComm (Age 52)CA, Dip., GAICD, Executive Director Comp: $439.17kDr. Michael GrahamHead of Discovery & Founding ScientistDr. Claudia KlothSenior Vice President of ManufacturingKey CompetitorsEdesa BiotechNASDAQ:EDSAMolecular TemplatesNASDAQ:MTEMNanoViricidesNYSE:NNVCEterna TherapeuticsNASDAQ:ERNAABVC BioPharmaNASDAQ:ABVCView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 16,701 shares on 3/11/2024Ownership: 0.645%Vanguard Group Inc.Bought 16,701 shares on 2/15/2024Ownership: 0.655%View All Institutional Transactions BNTC Stock Analysis - Frequently Asked Questions Should I buy or sell Benitec Biopharma stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Benitec Biopharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BNTC shares. View BNTC analyst ratings or view top-rated stocks. What is Benitec Biopharma's stock price target for 2024? 1 analysts have issued 12-month price targets for Benitec Biopharma's stock. Their BNTC share price targets range from $10.00 to $10.00. On average, they predict the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 90.5% from the stock's current price. View analysts price targets for BNTC or view top-rated stocks among Wall Street analysts. How have BNTC shares performed in 2024? Benitec Biopharma's stock was trading at $3.23 on January 1st, 2024. Since then, BNTC shares have increased by 62.5% and is now trading at $5.25. View the best growth stocks for 2024 here. Are investors shorting Benitec Biopharma? Benitec Biopharma saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 5,100 shares, a drop of 68.3% from the February 29th total of 16,100 shares. Based on an average daily trading volume, of 14,500 shares, the short-interest ratio is currently 0.4 days. Currently, 0.2% of the company's shares are short sold. View Benitec Biopharma's Short Interest. When is Benitec Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our BNTC earnings forecast. How were Benitec Biopharma's earnings last quarter? Benitec Biopharma Inc. (NASDAQ:BNTC) issued its quarterly earnings data on Tuesday, February, 13th. The biotechnology company reported ($2.64) earnings per share for the quarter. When did Benitec Biopharma's stock split? Shares of Benitec Biopharma reverse split on the morning of Wednesday, July 26th 2023. The 1-17 reverse split was announced on Wednesday, July 26th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 26th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. What other stocks do shareholders of Benitec Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Benitec Biopharma investors own include Amarin (AMRN), Pfizer (PFE), Amicus Therapeutics (FOLD), Sorrento Therapeutics (SRNE), Arbutus Biopharma (ABUS), Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Anavex Life Sciences (AVXL), BioLineRx (BLRX) and CRISPR Therapeutics (CRSP). When did Benitec Biopharma IPO? Benitec Biopharma (BNTC) raised $0 in an initial public offering on Thursday, August 6th 2015. The company issued 0 shares at $0.00 per share. BMO Capital Markets and Maxim Group LLC served as the underwriters for the IPO and Roth Capital Partners was co-manager. Who are Benitec Biopharma's major shareholders? Benitec Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (0.64%), Vanguard Group Inc. (0.65%) and Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of Benitec Biopharma? Shares of BNTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BNTC) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research Advisory Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Benitec Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.